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There exists a condition that some people – especially the pharmaceutical
industry – refer to as ‘male menopause’ and it is treated with male hormone
therapy (HT). The existence of male menopause is uncertain (e.g. Snyder 2004;
Rhoden & Morgenthaler 2004) and also the effects of HT have not yet been
clarified as being reliably safe. Nevertheless, new constructions of the male
menopause, currently being created on several platforms, consider it as a disease
or at least a condition that requires medical treatment. This study focuses on
some of those Finnish platforms where the meanings of male menopause are
constantly being constructed: popular magazines, medical textbooks, texts for
medical professionals, and web-pages. The final article presents quantitative
material on the distribution of male hormonal drug use in Finland.
The theoretical discussion on medicalization forms the conceptual core of
this study. The theoretical discussion has shifted in recent decades from that of
traditional medicalization to biomedicalization, with the Foucauldian concept of
biopower increasingly important in the research.
The research consists of an introductory section and four published articles
that together answer the question of the medicalization of male menopause.
1. The construction of male menopause in Finnish popular magazines
This part is based on articles on male menopause published between 1982 and
2002 in Finnish popular magazines. Male menopause is initially presented as a
social problem, but during the study period, writers increasingly present it as an
illness.
2. The making of an ageing disease: the representation of the male menopause
in Finnish medical literature
The data come from information provided for Finnish physicians about male
menopause during 1982–2002. It is found that disagreements about the male
menopause have been marked. Some authors describe it as a consequence of the
decline in gonad functioning that comes with increased age, and some have
argued that we are making a disease out of normal ageing. Its association with
sexual problems has clearly risen in prominence: libido and potency disorders
have recently been identified as symptoms.
3. Commercial web-based information on male menopause and male hormone
therapy
The material is drawn from private clinic websites, Finnish health websites, and
also from the websites of the male hormone manufacturers. This part provided a
4perspective on how lay people become health consumers. Different discoursive
formations are found in the material: healthism, a take-care-of-yourself
discourse, a quasi-professional discourse, an uncertainty discourse, a risk
discourse and a good sex discourse.
4. The first steps of testosterone therapy dissemination in Finland
This part uses quantitative data on drug distribution that originate from drug sales
statistics. The growth of male HT use was most vigorous in the capital area, as
would be expected when considering theories on the diffusion of medical
innovations.
This study as a whole shows that the interest in male menopause has risen and
that it is more and more treated. However, the number of users remains so small
that very firm conclusions cannot yet be drawn. Consumers and physicians in the
future are prepared to request and provide treatment on ‘male menopause’, if it is
found to be a real illness.
Key words: Medicalization, male menopause, male hormone therapy,
consumerism, biopower
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91 BACKGROUND
1.1 The commercialisation of ageing
In our post-modern society, health has value in itself. It is desired,
pursued and its loss is feared. According to Lupton (1995), we
live in a world where ‘the imperative of health’ predominates:
health represents a moral imperative that is embedded in our
social and cultural norms and is expressed in public policies.
Being healthy has become central to the construction of
subjectivities. Under the current discourse of ‘healthism’, the
pursuit of good health is an end and a goal in itself. Increasingly,
health is also viewed as a commodity and individuals are defined
as health care consumers who ‘buy’ health. This consumer
discourse plays a part in constituting social subjects and relations
between subjects (Lupton 1995; Henderson & Petersen 2002;
Irvine 2002).
The average life expectancy in Western countries has never
been as high as it is nowadays. Now the great post-war baby
boomer generations are in their fifties and sixties, and they in
particular place great importance on living a vigorous old age
(Butler 2000a, 3; Haber 2000–2001). In Finland this baby boomer
generation is, in relative terms, the largest in the world (Karisto
2005, 22; Valkonen 1990, 230), and this group is accustomed to a
high standard of living and to a consumer lifestyle (e.g. Heinonen
2005).
Even though the number of older people has grown rapidly,
this does not, however, mean that getting old would be a self-
evident and natural phase in life. Quite the contrary: several social
gerontologists have pointed out how the social meanings of old
age have changed. One of the most important trends is the
medicalization of old age (e.g. Ebrahim 2002). Many physio-
logical changes that previously were interpreted as a sign of a
phase of life have become either signs of potential illness or
something that should be treated medically. While in the 1950s
the ending of menstruation and the feelings attached to it were
seen as normal signs of ageing, now in the 2000s that change is
thought to require treatment. The research of Päivi Topo (1997)
describes the medicalization of female menopause in Finland.
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Female hormone therapy for menopause has been on the
market for decades and it is quite a normal treatment for active
women in their fifties. However, hormone therapy for female
menopause is now under reconsideration as a result of the
findings of two major studies (Grady et al. 2002; Writing Group
for the Women’s Health Initiative Investigators 2002) that suggest
female hormone therapy may be risky.
Until now, men have been left alone in their ageing process,
but will this be true of the future? Pharmaceutical companies are
always searching for new target groups. According to Moynihan,
Heath and Henry (2002), selling sickness and “disease
mongering” are the themes of today’s pharmaceutical marketing.
By “disease mongering” Moynihan, Heath and Henry (2002)
mean extending the boundaries of treatable illness to expand
markets for new products. Disease mongering can include turning
ordinary ailments into medical problems, seeing mild symptoms
as serious, treating personal problems as medical, seeing risks as
diseases and framing prevalence estimates to maximise potential
markets (Moynihan, Heath & Henry 2002, 886). In the winter of
2005–2006 this was seen in Finnish pharmacies when there was
an ‘informative’ campaign’ about testosterone deficiency. Men
were advised to check their testosterone levels via a questionnaire
on the Internet and then to consult a physician.
According to Conrad (2005), the pharmaceutical industry has
become an increasingly important agent in medicalization. The
industry looks for new customer groups more aggressively than
before. This kind of shift has already happened in wealthy
countries where more money is now invested in research into the
prevention of diseases than into treatments (Freemantle & Hill
2002, 864–5; Heath 2005, 955). In Finland, the situation is no
different (e.g. Klaukka 2005b). Healthy men are encouraged to
consider themselves as ill and to become paying customers of
medical practitioners and pharmacists.
The theme investigated in this study, male menopause, is one
example of a new kind of situation facing health policy makers.
As medicalization grows increasingly and develops new formulas,
society has to more and more treat symptoms that in themselves
are not illnesses as such, but which may constitute a lack of well-
being or risks for sickness. I see male menopause as just one of
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these kinds of states. From the perspective of health policy, such
expansion through medicalization is unsustainable. Although our
health care system has never been as efficient as it is now, it
remains in crisis (e.g. Häkkinen 2003). The outcomes of these
economic and social changes are problematic.
Finnish health policy is based on both a public health care
system and on a commercial, private health care sector, the latter
of which is partly reimbursed by the Social Insurance Institution
of Finland (SII, KELA). Increasing amounts of money are spent
on medicines and all the time new treatment possibilities are
being developed (e.g. Klaukka & Idänpää-Heikkilä 2006). That
leads us towards the question of which treatments for its citizens
should or should not be paid for by society. Finnish health policy
discussion today centres mostly on prioritisation: We have to
make hard choices in allocating scarce resources and in
prioritising health care (e.g. Ryynänen et al. 1999a; Ryynänen et
al. 1999b; Liss 2003; Saarni & Vuorenkoski 2003). Patients,
patient organizations, the pharmaceutical industry, doctors’
associations, and political actors are all participants in discussions
on prioritisation.
The topic of this PhD thesis is the construction of the male
menopause as an illness and how it is linked to hormone therapy,
the rapid ageing of the population (Räty et al. 2003),
medicalization, and to changes in health care. Even though the
environment of this study is Finland, the phenomenon is global;
populations are ageing in all industrialised countries and remedies
to delay the effects of ageing are being aggressively developed
and marketed to both women and men. The growing population
of affluent, older people have high expectations of medical care,
fuelled by both consumerism and the promotion of new medical
technologies by doctors and the pharmaceutical industry
(Ebrahim 2002). The approach of this study is in keeping with
Gray and Phillips (1995), who suggest using sociological means
to make a statement on current health policy.
12
1.2 Male menopause and male hormone therapy
The broader social context of this study is the medicalization of
the phenomenon called male menopause and its treatments. The
existence of the male menopause is a disputable matter. Some
experts believe that a reduction in testosterone as men grow older
is responsible for male menopause. Testosterone levels fall at a
rate of one per cent per year after mid-life, and symptoms of
testosterone deficiency include depression, irritability, sexual
dysfunction, fatigue and problems with mental functioning.
Unlike women’s rapid decrease in blood oestrogen levels during
and after menopause, men experience a gradual decrease in
plasma testosterone levels. At the age of 75 years, over 75 per
cent of men have bio-available testosterone levels below the
normal minimum of young adults (Morales, Heaton & Carson
2000; Vermeulen 2000; Tapanainen 2001).
Whether men undergo a physical process similar to female
menopause has been under discussion since the 1970s (e.g.
Featherstone & Hepworth 1985), but there is still no unanimously
agreed upon opinion (e.g. Snyder 2004, 440). The debate on the
existence of the male menopause continues to rumble on (e.g.
Rhoden & Morgentaler 2004). It is therefore an exaggeration to
compare male menopause to female menopause. As a societal
phenomenon, male menopause has until now not been studied,
even though there have been predictions that every other man
would be using testosterone treatment by 2004 (Goodwin 2001).
In the 1980s and 1990s male menopause has gained greater
legitimacy and social acceptability, and the surrounding
terminology has become accepted within consumer culture
(Hepworth & Featherstone 1998, 276). As this study will show, in
Finland the term became common by the end of the 1990s.
The term male menopause will be used in this study without
quotation marks for brevity, even though the author remains
aware that such a phenomenon may not exist. The term
andropause will also be used in a like manner (e.g. Gould, Petty
& Jacobs 2000; Goodwin 2001).
Testosterone therapy is the main treatment for male
menopause that is defined as low testosterone levels (e.g.
Committee on Assessing the Need for Clinical Trials of
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Testosterone Replacement therapy in the Institute of Medicine
2004). Testosterone was first isolated in 1935 and there was an
article on male menopause in a medical journal as early 1939
(Werner 1939). Despite that, hormone therapy for men is one of
the few areas of medicine where research on men lags behind that
on women (Lacayo 2000). In spite of an acknowledged lack of
information about men’s ageing, it has still become a target for
medical treatments, and considerable efforts have been invested
into developing treatments for male menopause. For example one
of the world’s largest pharmaceutical companies has had a
significant focus on research into men’s hormones (Schering AG
2001).
There is a widespread understanding that differences in the
prevalence of CVDs (cardiovascular diseases) are due to higher
testosterone concentrations in men, and therefore testosterone
supplementation in men would adversely affect plasma
lipoproteins and increase the risk of atherosclerotic heart disease.
However, there is no data showing the cause-and-effect
relationship between androgens and cardiovascular disease (e.g.
Bhasin & Herbst 2003, 1929; see also Riska 2004). The available
data suggest that serum testosterone levels in the range that is
mid-normal for healthy young men are consistent with an optimal
cardiovascular risk profile at any age, and testosterone
concentrations either above or below the physiologic male range
may increase the risk of atherosclerotic heart disease (Bhasin &
Herbst 2003, 1930). According to Fukyi et al. (2003), low
testosterone levels are linked to atherosclerosis in men with Type
2 diabetes.
Amory et al. (2004) presented quite impressive results from a
placebo-controlled clinical trial evaluating the effect of
testosterone therapy on hip and spine bone density in older men
with low testosterone levels. According to them, older men,
particularly those with low serum testosterone, might benefit from
testosterone therapy through improved bone mineral density and
reduced risk of fracture. In the same issue, however, Barrett-
Connor and Bhasin (2004) asked if the results of Amory et al.
(2004) were clinically relevant, and called for more research on
testosterone. According to Muller et al. (2005), higher testos-
terone levels are associated with better cognitive performance in
14
the oldest old category, which was in their study the group aged
70–80. Earlier, Moffat et al. (2004) found that calculated free
testosterone levels were lower in men who developed Alzheimer
disease. In 2006, Shores et al. found that low testosterone levels
were associated with increased mortality in male veterans, but
called for more research on the issue.
In the USA, testosterone prescriptions have jumped 170 per
cent since 1999 (Geriatrics 2004, 15; Committee 2004, 24) and
1700 per cent between 1994 and 2003 (Bhasin et al. 2003, 299),
even though its value remains unproven. To date, clinical trials
have been short, with small numbers of participants, and it is not
expected that effects on long-term prostate outcomes would be
evident. Prospective studies have demonstrated a low frequency
of prostate cancer in association with testosterone therapy
(Rhoden & Morgentaler 2004, 486). A large clinical trial to
determine testosterone’s risks and benefits was stopped in the
USA mainly because of the concerns that testosterone could spur
the growth of prostate cancer (Kolata 2002). According to
Richard Hodis, the director of the US National Institute on Aging,
we are in many ways where we were decades ago with oestrogen
replacement in women in terms of understanding the role of
testosterone therapy (Kolata 2002).
According to present knowledge, testosterone therapy itself
does not cause, for example, prostate cancer. However,
testosterone may accelerate the growth of an already existing
tumour (Committee 2004, 93). This lack of consensus about the
potential risk is interesting since it highlights the disagreement
about where to draw the line between a benign and malign growth
lie.
According to Lawrence (2003), a US panel urged caution on
testosterone therapy, since larger-scale trials on its efficacy and
safety are needed before widespread use could be recommended.
Internationally, the growing interest in testosterone use is
reflected in greater public and media attention (Bhasin, Singh et
al. 2003, 299). In this thesis, one main interest lies in how
androgen preparations specially designed for treating ageing
males have entered the Finnish market.
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2 MAIN APPROACHES
The sociology of health and illness represents sociological
research focussed on health, illness, medicine and health care and
both qualitative and quantitative methodologies are utilised.
Medicalization is primarily a matter of defining already
problematic behaviours in medical terms and is central to this
sociological field (Rosenfeld & Faircloth 2006, 3). For Peter
Conrad (2000, 32) medicalization is “defining a problem in
medical terms, using medical language to describe a problem,
adopting a medical framework to understand a problem, or using
a medical intervention to ‘treat’ it. Medicalization occurs when a
medical frame of definition has been applied in an attempt to
understand or manage a problem.”
The concept of medicalization and the theoretical and
empirical elaboration of it has been an important outcome from
research that has critically analysed the nature of medical
knowledge. The term medicalization refers to the ways in which
medicine expands into new arenas that were previously not
defined as part of the medicinal field. The concept was brought
into use by Irving Kenneth Zola more than 30 years ago (1972).
The core idea of medicalization is the way in which categories of
illnesses, the meanings of health, and the number of treatable
diseases expand. Medicine defines the boundary between normal
and abnormal (Armstrong 2000).
The theoretical discussion on and researching of medicaliza-
tion form the conceptual core of this study. However, the
theoretical discussion has changed during recent decades – as has
to some extent the phenomenon of medicalization – from
traditional medicalization to a biomedicalization, with the the
Foucauldian concept of biopower increasingly important in
research.
I am not a strict adherent to any particular tradition. A
theoretical discussion of and research on medicalization form the
conceptual core of this study. However, because the theoretical
discussion – as well as possibly the phenomenon of medicaliza-
tion – has changed during the last decades from traditional
medicalization towards biomedicalization, the Foucauldian
concept of bio-power is likewise important in this study. In taking
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part in the medicalization discussion, I am critical towards the
tendency for medicalization, since the power definition of
medicalization if often quite one-dimensional. Further, by
reviewing the medicalization of ageing I seek to contribute to the
discussion of ageing and its related health policy discussions, as
well as seeking to highlighting the connection between health
culture and rising health care expenses. I am also interested in the
relationship between medical knowledge and evidence-based
medicine and the discussion on prioritisation.
2.1 Medicalization and medical social control
Traditional medicalization theory originates in the first place from
labelling theory. Medicine can be used as a mechanism of social
control. Talcott Parsons was the first to understand medicine as a
controlling institution with his ‘sick role’ theory in 1951.
According to Parsons, the role of a physician has an important
function that may be characterized as functions of “social control”
in a well-established sociological sense (Parsons 1978). Medical
social control means the ways in which medicine functions to
secure adherence to social norms by using medical means to
minimise, eliminate, or normalise deviant behaviour. As generally
understood, medical social control is the acceptance of a medical
perspective as the dominant definition of certain phenomenon
(Conrad & Schneider 1980a). Another early sociologist who
claimed that medical experts should be granted a certain
autonomy in their researches, diagnoses, and recommendations
for treatment was Freidson (1970).
Irving Kenneth Zola was first to claim that medicine is
becoming a major institution of social control (1972). Labelling
theory emerged as a result of social psychology’s focus on micro-
sociological symbolic interactions, and a central tenet is that
deviance is “collective action”. Drawing from interactionist
labelling theory (Pfhol 1985), Conrad and Schneider termed the
transformation of social problems from the jurisdiction of law to
that of medicine as moving “from badness to sickness” (Conrad &
Schneider 1980a; Clarke et al. 2003.) Labelling theory views
deviance as relative to time, place, and audience and as an
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attribute conferred on people by others. Rather than being viewed
as an objective social condition, deviance would be regarded as a
social product produced by the joint action of the “deviant” and
various social audiences (Conrad & Schneider 1980a, 18).
In the years to follow, social scientists like Talcott Parsons
(1951), Eliot Freidson (1970) would join the discussion of
medicalization. Zola sought to use the term to theorize on the
extension of medical jurisdiction and practices into increasingly
broader areas of life. By medicalization Zola initially conceived
how particular social problems deemed morally problematic and
often affecting the body were moved from the professional
jurisdiction of law to that of medicine (Clarke et al. 2003, 164).
According to Conrad and Schneider (Conrad & Schneider
1980b; Conrad 1992), medicalization occurs at three distinct
levels: conceptual, institutional, and interactional. On the
conceptual level, medical terminology is used to define the
problem, while the medical definition also comes into general
use. On the institutional level, organizations may adopt a medical
approach to treating a particular problem in which the
organization specialises. On the interactional level, medicalization
occurs as part of doctor–patient interaction, that is, when a
physician defines a problem as medical or treats a social problem
with a medical form of treatment. According to Conrad and
Schneider, there are also social factors that encourage or abet
medicalization: the diminution of religion i.e. secularisation, an
abiding faith in science, rationality and progress, the increasing
prestige and power of the medical profession, and the penchant
for technological solutions to problems. Even though these factors
don’t explain the increase of medicalization, they do provide the
context (Conrad & Schneider 1980b; Conrad 1992).
Conrad and Schneider also contend that (Conrad and
Schneider 1980b; Conrad 1992) in a medicalised world, belief in
science is pervasive: science has enabled us to do things and solve
problems more easily. Health is used as a justification of
controlling power operations and as a criterion for defining
activities as deviant. Thus, there is a deep-seated belief in medical
technologies or in science in general, both as ‘good’ and as
essential to ‘progress’. The sick are considered ‘deviant’, and this
serves as justification for the treatment and control of such
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undesirable persons. In this way, the medicalization of a
phenomenon can be considered a political achievement (Conrad
& Schneider 1980a, 265, 273). All of the above-mentioned can be
referred to as traditional medicalization.
Structural sociology gives an additional background to the
theories of traditional medicalization. Current medicine and its
structures can also be seen as dominant and promoting of the
capitalist interests of medicine as well as broadening the medical
industry complex (e.g. Navarro 1986; Clarke et al. 2003). The
expanding status of service markets and medical treatments make
it a profitable industry and has bolstered its status as a source of
social control, since medicine is depicted as strengthening both
the mechanism and the ideology of capitalism. Medicine is also
depicted as political since it helps to regulate populations, define
acceptable behaviour, and to individualise and decontextualise
political issues (Waitzkin 1991).
Earlier, Waitzkin (1989) demonstrated a link between the
class structures of capitalism and the micro-level structures of
clinical settings. He also showed how the doctor–patient
relationship reflected class structures. According to Waitzkin
(1989), doctors on the one hand voice the explicit ideological
messages that legitimate the current class-structure of society. In
the doctors’ equating of health with economic productivity, the
doctors maintained the social relations of capitalism. On the other
hand, according to Waitzkin (1989), doctors implicitly act as
agents of social control while enforcing these ideologies, and
acting as agents of medicalization (White 2002, 92).
To explain the history of another model of medicalization,
namely that of biomedicalization, we must return to the origins of
allopathic medicine, with the emphasis on an important period
between 1880 and 1945 in the United States. This first era of
‘scientific’ medical transformation centred on professionalism,
specialisation, and nursing, but also on the creation of an allied
health care profession and on the elaboration of new social forms
(e.g. hospitals) (Clarke et al. 2003, 163).
After the World War II, the growth of medicine in the USA
as a politico-economic sector and as a sociocultural “good” was
dramatic, and was driven by major investment, both private and
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public. The production of medical knowledge and clinical
interventions also expanded rapidly.
“Then, in the beginning of about 1985, the nature of
medicalization itself began to change as technoscientific
innovations and associated new social forms began to transform
biomedicine from inside out. Moreover, it is claimed that
nowadays a tendency exists towards biomedicalization (Clarke et
al. 2003).” Clarke et al. argue that biomedicalization can be
defined by “largely technoscientific changes in biomedicine”
which include “technoscientific innovations in the form of
molecular biology, biotechnologies, genomization, transplant
medicine, and the new medical technologies” (161–162).
Biomedicalization means that health itself and chronic illnesses
are becoming individual moral responsibilities to be fulfilled
though improved access to knowledge, self-surveillance,
prevention, risk assessment, the consumption of appropriate self-
help, biomedical goods, and services (Clarke et al. 2003, 162). In
the era of biomedicalization, innovation and interventions are also
“technologies of the self” (Foucault 1988), i.e. forms of self-
governance that people apply to themselves.
Clarke and her colleagues have defined five key processes
that both engender biomedicalization and are produced through it:
“(1) the political economic reconstitution of the huge sector of
biomedicine; (2) the focus on health as a moral obligation and the
elaboration of risk factors and self-surveillance; (3) the
increasingly technological and scientific nature of biomedicine;
(4) transformations of information and the production and
distribution of knowledges; and (5) transformations of bodies to
include new properties and the production of new individual and
collective technoscientific identities.” (Clarke et al. 2003.)
Conceptually, biomedicalization is predicated on what we see
as larger shifts – the progress from the problems of modernity to
the problems of late modernity or postmodernity. That means that
the shift to biomedicalization is a shift from an enhanced world
that arches over external nature (e.g. the world around us) towards
a transformation of internal nature, often transforming life itself.
Technologies are a set of techniques and practices that can be
deployed to modify or affect the self and these techniques are
historically situated within power relations. They also have a
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productive side but also a constraining side (Foucault 1988). Here
I find the many similarities with the Foucauldian concept-
tualisation of the technologies of the self: both Clarke et al.
(2003) and Foucault (1988) suggest focusing on health and
monitoring oneself and to obeying biomedical surveillance. Also,
biomedicine controls life without question and an individual has a
moral obligation to obey and to gain access to knowledge of his
medical status. Self-surveillance is emphasised both by Foucault
(1988) and Clarke et al. (2003).
Conrad (2005) lists three changes in medical knowledge that
have, according to him, engendered an important shift in the
engines that drive medicalization: biotechnologies – especially
those of the pharmaceutical industry and genetics – consumers,
and managed care. Conrad also pays attention to Clarke et al.’s
(2003) paper and writes that the conception of biopower loses
focus in terms of definitional issues, which have always been a
key to medicalization studies according to his mind. Neither does
Conrad sees us as having moved to a postmodern phase.
According to Conrad (2005), medicalization is expanding, but he
only sees shifts where Clarke et al. (2003) see transformations.
Conrad and Schneider (1992) list some examples of medicali-
zation: a continuing medicalization of madness, the medicaliza-
tion of drinking problems i.e. alcoholism, opiate addiction,
homosexuality (see also Conrad & Angell 2004), child abuse and
family violence (Conrad & Schneider 1992, 280–286). The latest
examples are the medicalization of compulsive buying (Lee &
Mysyk 2004) or the diagnosing of Attention Deficit/Hyperactivity
Disorder (ADHD) and the use of the drug Ritalin® among the
school-age population to control ADHD children (Singh 2004).
There are many examples that exemplify medicalization
processes applicable directly to men. A recent case has been the
medicalization of male sexual dysfunction. Viagra debuted in
1998; according to a Finnish study, some sort of erectile
difficulties affect about 67 per cent of 50-year-old men, and when
it comes to those aged 70, the percentage is as high as 76 per cent
(Koskimäki et al. 2000; Koistinen & Ruutu 2005). Nowadays
there are also competing pharmaceuticals in Viagra®: Levitra®
and Cialis® (Wienke 2006). In 2003, a well-known urologist even
recommended daily Viagra® to prevent impotence (Moynihan
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2003a). Erectile dysfunction causes serious distress, but according
to Tomlinson and Wright (2004) the hyperbole of Viagra® by the
media is also stressful for men who have tried to use Viagra®
without success (Tomlinson & Wright 2004).
Another example that illustrates the process of medicalization
is baldness, which has only recently begun to become
medicalised. First, there were treatments invented for baldness.
The invention and availability of medical therapies are seen to be
the driving forces of medicalization (Szymczak & Conrad 2006,
102). Men have been worried about their loss of hair throughout
history but only in recent years have we begun to understand that
male baldness has a connection with male hormones i.e.
androgens. Thus, male baldness was named androgenetic alopecia
(Szymczak & Conrad 2006).
There are both surgical and pharmacological treatments for
androgenetic alopecia. Surgical treatments typically involve
transplants using a graft technique, scalp reduction, or scalp flaps.
Pharmaceutical treatments involve two pharmaceuticals:
Rogaine® and Propecia®. Rogaine® has an active ingredient
called minoxidil, which was initially aimed at lowering blood
pressure, but was noticed to cause hair growth as a side effect.
Volunteers wanted to try this medication for baldness as well, and
in the 1980s, physicians were prescribing minoxidil to their
balding patients. The FDA (Food and Drug Administration of the
United States) granted minoxidil – that is Rogaine® – approval as
a treatment for baldness on August 18, 1988. (Szymczak &
Conrad 2006). In Finland Rogaine® is now an over-the-counter
medication.
At the end of 1997 the FDA approved another hair loss pill,
Propecia®, which is suitable for men who have just discovered
that they suffer from hair loss. To gain the benefits, men must
take Propecia® for the rest of their lives. Propecia® is targeted at
self-conscious men who worry about their hair loss telling them
that balding is preventable (Szymczak & Conrad 2006). In
Finland, Propecia® is a prescription medication.
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2.3 Medical knowledge, discourse and biopower
Freund and McGuire (1991) put forward the notion that even
though Western medicine is based upon scientific knowledge, the
practitioners themselves are not typically scientists. Instead, their
goals are more pragmatic: To deal with the specific condition of
individual patients or clients, which is quite understandable
considering the vast amount of medical knowledge. What the
practitioner needs to know is likewise more practical. The only
proportion of medical knowledge relevant is that which relates to
conditions they are most likely to encounter in clinical practice.
Much medical knowledge is thus ‘recipe knowledge’ or ‘know-
ledge limited to pragmatic competence in routine performances’
(Berger & Luckmann 1967, 42). Access to and possession of
specialized, formal knowledge, such as medical knowledge, is
particularly uneven. However, because very few people in
modern societies possess advanced medical knowledge or
technical skills, being able to control such knowledge is the basis
of rewards, power, and privilege. That way, people who control
specialized knowledge are in a position to limit the access of
others to that knowledge (Freund & McGuire 1991).
The concept of discourse brings together language, visual
representation, practice, knowledge, and power relations.
Language and visual imaginary are replete with power relations
and the construction of knowledge and practice about phenomena
(Lupton 2000, 51). Discourse is viewed as a form of social
practice, as a mode of action as well as a mode of representation
(Fairclough 1992, 63). The discourses that tend to dominate over
others are those emerging from powerful individuals or social
groups and they help them to further their interests in shaping the
ways in which phenomena are represented. The discourse in the
medical sciences relies partly on the assumption that medicine
would be politically and culturally neutral (Lupton 2000, 52).
Michel Foucault, one of the important recent social
constructionists, presented theories on bio-medicine (in The Birth
of the Clinic, 1973), power, knowledge and discourse, while
taking into account the idea that medicine is not politically
neutral. According to Foucault, the truth is produced in
discourses, and discourses themselves act as a truth, even though
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being neither true nor false (Foucault 1980a, 115–119).
Discourses are, for Foucault, practices that systematically form
the subjects which they speak about (Foucault 1972, 49, 79–125).
Power relations and scientific discourses reciprocally constitute
each other: in short, discourses produce societal phenomena
(Foucault 1972, 31–76, 107; Foucault 1979, 25–28; Harding
1997). Foucault’s approach was to say that the body is produced
by knowledge in discourses or that the body is an effect of
practices which embody such forms of knowledge (Turner 1992,
52). According to Foucault, power is productive and fabricates
truth, and he speaks of the tie between power and knowledge.
According to Foucault, starting in the 17th century, biopower
(literally having power over other bodies) evolved in two basic
forms: these forms were not antithetical, however; they
constituted rather two poles linked together. One of these poles
centred on the body as a machine: the disciplining of it, the
optimisation of its capabilities, the parallel increase of its
usefulness and its docility, and its integration into systems of
efficient and economic controls – this all encompassed an
anatomo-politics of the human body. The second pole focused on
the species of body, life expectancy, and longevity. Their
supervision was effected through an entire series of interventions
and regulatory controls: a biopolitics of the population. The
disciplines of the body and the regulations of the population
constitute the two poles around which the organization of power
over life was deployed. All this was, according to Foucault,
biopower, which coerced bodies into the machinery of production
and adjusted populations to economic processes. Biopower is
subtle and is always evident, everywhere; it shapes the problems
that call for medical and governmental interventions (Dreyfus &
Rabinow 1983; 134–5, Foucault 1979; Foucault 1980b, 135–141;
Gastaldo 1997, 115–116; Hewitt 1991; Samuelssen & Steffen
2004).
Docile bodies created via power – knowledge were needed
for the labour force, since biopower was without question an
indispensable element for the development of capitalism, and
medicine assisted in this process (Foucault 1980b, 140–141.). The
body was seen as a machine. That is why one can say that
biological life is a political event where a population’s
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reproduction and disease control are central to economic
processes and therefore are subject to political control (Gastaldo
1997). Gordon (1991, 28) suggests that biopower is the link
between micro and macro levels since it is a politics concerned
with subjects as members of a population, in which issues of
individual sexual and reproductive conduct interconnect with
issues of national policy and power (Gastaldo 1997, 113–115).
According to Foucault, biopower creates problems that call
for medical (i.e. personal) and governmental (i.e. larger-scale)
interventions. Biopower is also very regulative (Foucault 1979;
Hewitt 1991, 234–235). A consequence of the development of
biopower is the growing importance assumed by the action of the
norm, at the expense of the juridical system of the law. A
normalizing society is the historical outcome of a technology of
power centred on life (Foucault 1980a, 143–144).
If looked at in this way, one’s health is not a private matter or
a question of naturally occurring things: There are many actors in
constructing and negotiating an illness. For example, first, there is
the human being himself; then there are doctors who prescribe
medications or hospitalise the one who is ill. Doctors have to
follow instructions that they are given from the Ministry of Social
Affairs and Health. And then, all the time, there is the
pharmaceutical industry seeking to affect patients and doctors.
Sponsoring or establishing patient organisations is one way of
achieving this effect but more important is indirect advertising.
Pharmaceutical companies are trying to expand the need for their
medications and thus, the social construction of an illness would
be replaced by the corporate construction of disease (Moynihan,
Heath & Henry 2002).
Foucault also used the term ‘technologies of the self’ in
understanding how single human beings regulate themselves, and
especially their bodies (Foucault 1988). He also paid attention to
the development of medical discourse especially in his works
Madness and Civilization (1973b) and in The Birth of the Clinic
(1973a). According to Featherstone and Hepworth (1991) and
also Turner (1991), civilized man uses a battery of internal
techniques of self-mastery and restraint. These technologies of the
self grew out of and presuppose a complex array of technologies
of the body (Martin, Gutman & Hutton 1988). The technologies
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of the self are the internal technologies of the self by which
human beings regulate themselves as an individual (Helén &
Jauho 2003).
In this study I aim to show how social phenomena become
visible through medical control. That is included in the discussion
of biopower: medical knowledge makes sense of our problems by
making them medical problems, the treatment of which is built
discoursively in that knowledge.
2.4 Study aims
The central aim of the study is to investigate the medicalization of
men’s midlife and the dissemination of male hormonal treatments
(HT) in the context of Finnish health care. A more general aim of
the research is to discuss the limits of an illness and to debate
whether the normal ageing of a human being is any longer
acceptable. This study is based on four sub-studies which are
presented as articles I–IV.
The study will open up discussion about the medicalization of
men’s ageing and will analyse the content of information on male
menopause provided for lay people (Article I) and will analyse
how the definition has changed in Finnish medical training
(Article II) and in the professional literature of the period 1982 to
2002 (Article II). The aim is also to investigate what information
is available on the Internet on male menopause and its treatment
in Finland and to compare the web-based information to the best
available medical information about the male menopause and its
treatments (Article III). Finally, the developments of male
hormone use in Finland during the last decade are also studied,
asking whether a typical male HT user can be discerned in the
population-based health survey data (Article IV).
According to Zola (1972), the key element in a sociological
perspective on medicine is to see the ways in which diseases are
labelled and treated as forms of social control, and that what is
labelled a disease may only tangentially be linked to a biological
occurrence in the body (Zola 1972). Medicine has, according to
Zola (1972), become the major institution of social control and
has replaced the traditional controlling institutions of religion and
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law. When medical perspectives of certain problems and their
solutions become dominant, they diminish other possible ways of
understanding that problem (see Malin 2006). Concretely,
medical social control is enacted through professional medical
intervention, via medical treatment. These interventions aim at
returning ‘sick’ individuals to their conventional social roles or
adjusting them to new roles, or making individuals more
comfortable with their conditions (Conrad & Schneider 1980a).
There are different forms of medical social control. Male
menopausal hormone therapy is an example of medical social
control, namely medical technology (including pharmacy), but
there also are three other forms: 1) medical collaboration,
meaning doctors assist as information providers and gatekeepers,
2) medical ideology, which means that doctors impose a medical
model primarily because of the accrual of social and ideological
benefits, and 3) medical surveillance; medicine is part of an
extensive system of moral regulation of populations through the
medical regimen (Conrad 1979; Conrad 1992; Turner 1997).
The emergence of organised sub-specialties in medicine has
also been associated with innovations in social control; for
example paediatricians took on the professional supervision of
healthy children, while the psychosocial problems of children
became gradually medicalised. The routinisation of paedi-
atricians’ work preceded a behaviourist turn in paediatrics. ‘A
new paediatrics’ was a vehicle for academic generalists to secure
a place in medical schools dominated by sub-specialists. Pawluch
explained this ‘new paediatrics’ by means of market trends
(Halpern 1990; Pawluch 1983; Conrad 1992, 214–215). The rise
of a specific specialty is now happening with ageing men, who
have their own doctors’ subspecialty, that of andrology, which
was legally formulated in Finland in 2001. It is for this reason that
we must think of disease as being to a large degree a social
process as well as a biological product of nature. Sickness and
disease are part of the ongoing social processes of life (White
2002, 41).
The discussion section questions what kind of health we are
to pursue and at what cost, in economic, social and cultural terms.
In this study, society is seen as being at a turning point in how it
defines ‘health’. Understanding of the dynamics and processes of
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medicalization is important especially now when the health care
system is trying to overcome current and future challenges, with
the needs and treatment possibilities increasing faster than the
available resources. The study will discuss what the future of
Finnish health care would and could be like.
Medicalization and biopower are fruitful concepts to
elaborate the phenomenon that I am studying. Via medicalization,
social phenomena come to be visible and thus, are put under
medical control. Via biopower, medical knowledge superimposes
itself on social phenomena and analyses them as medical
problems, the treatment of which is discoursively built through
that knowledge.
The medicalization trend aims at making a man the subject of
medicine, which operates as an external biopower. When the man
adopts Foucauldian self-surveillance, he can move to a more
autonomous class of biomedicalization and will start to monitor
their own risk behaviour and health. Biopower is a means of
understanding the outside influences on people that they
themselves might not necessarily notice.
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3 MATERIALS AND METHODS
The qualitative and quantitative research material used describes
the processes of medicalization at a societal level and the use of
hormone therapy at the population level.
As male menopause is a new phenomenon, the analysis was
focused around textual material, sales statistics and population-
based health survey data (Health 2000): for example, it would
have been illogical to make a survey focussing on male
menopause and its treatment since a very large group of men
would be needed to identify the few testosterone users. Using the
existing Health 2000 Survey from the National Public Health
Institute, with results on the use of medications, gave an
understanding of the dissemination of a new medical technology.
The textual materials included in the study data are meant to
be informative and/or offer information on male menopause. One
type of data used here are lay press articles, which popularise
medical research and at the same time create images of sickness
and health for its readers. Medical study materials such as
textbooks socialize students into the habits of medicine, while
journals for medical professionals keep physicians up to date with
the progress of medical science. The diversity of opinions within
medicine is expressed in the medical journals. Both these types of
data as well as the Internet are used in this study. The Internet is
the most accessible forum and provides all kinds of information
about male menopause.
3.1 The normalisation of the treatment for male
menopause
The first article was based on popular magazines that were
available to everybody, so they had the potential to effectively
alter the public atmosphere. Male menopause was a relatively
new phenomenon and is closely tied to ageing, thus the role of
popular magazines as an information source was worth studying.
The construction of male menopause was studied by
examining articles published on the topic between 1982 and 2002
in Finnish popular magazines. A total of 35 articles published in
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the Finnish lay-press between 1.1.1982 and 31.12.2002 formed
the basis of the analysis. The words used in every search were
‘hormone treatment’, ‘male’, ‘menopause’, ‘testosterone’, ‘andro-
pause’ and ‘andrology/andrological’. The method used was data
classification and text analysis, with Atlas.TI used as the software
program. The data were encoded in the Atlas.TI program and
analysed thematically. Chronological changes were also observed.
3.2 Finnish Medical Society approves andrology
Previous studies have shown that current medical practice is
reliably represented in the contents of medical journals (e.g.
Moncrieff & Crawford 2001; Carter 2000). The aim of the article
was to examine how the male menopause has been constructed
and described, and how the definition has changed in Finnish
medical training and in the professional literature during 1982–
2002. More specifically, the aim was to clarify how the causes of
male menopause and menopausal symptoms have been
represented and what recommendations have been given for
treatment, and finally, what were seen as the indications and
contra-indications for male hormone therapy (HT).
The principal sources were research papers, editorials,
reviews and letters in the two main Finnish medical journals,
Suomen Lääkärilehti [The Finnish Medical Journal] and
Duodecim [The Journal of The Finnish Medical Society
Duodecim]. Study textbooks were also included. The keywords
used to search the journals’ electronic files were ‘hormone
treatment’, ‘male’, ‘menopause’, ‘testosterone’, ‘andrology/
andrological’, and ‘andropause’. A total of 40 documents from
the medical journals were identified for inclusion in the analysis,
and 17 documents from the textbooks. The method was a
combination of thematic analysis and text analysis, while the
Atlas.TI software program was used as a tool.
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3.3 Persuading Finnish men to use testosterone
This study investigated what information a man living in Finland
was able to find on the Internet about so-called male menopause
and its treatment. Secondly, the web-based information was
compared to the best available medical information about the
illness and its treatments. Drugs for male menopause are
prescription drugs, the marketing of which is illegal in Finland,
and it was thus interesting to investigate how the marketing of
pharmaceutical products worked on the Internet.
The criteria for all WWW sites to be included in the study
were that they were accessible to lay people. It was attempted to
imitate the likely path used by a man searching for information on
ageing and/or menopausal symptoms. Firstly, the Google search
engine was used in the autumn of 2004 to obtain information in
Finnish about male menopause, male clinics and male hormone
therapy using the Finnish words ‘mies’ (man or male) and
‘klinikka’ (clinic) in the search string. Secondly, the material was
searched using so-called chain sampling (Miles & Huberman
1994, 28); in other words, one source of information providing
links to other sources. Altogether 98 primary documents, that is
individual web sites, were found. The texts were analysed by
thematic content analysis, while the Atlas.TI software program
was used to help in analysis.
3.4 The growth of testosterone sales
The study centred on how male hormone consumption had
developed in Finland during the last decade. The study was based
on statistical information on Finnish drug sales from 1993 to
2004.
In the Anatomical Therapeutic Chemical (ATC) classification
system, the drugs are divided into different groups according to
the organ or system on which they act and their chemical,
pharmacological and therapeutic properties (WHO 2005). The
drugs studied here belong to the ATC group G03BA03
testosterone, which is a sub-group of the G03BA group (WHO
2005).
31
In this study, three statistical data sources were used:
1) Drug sales statistics were received from Finnish
Pharmaceutical Data Ltd (Suomen Lääkedata Oy, SLD),
which is a leading producer of information about the
pharmaceutical market. The statistics category used is
known as SLD Pharma. All sales figures were wholesale.
The computing units were sales in euros, units, and
treatment days. The SLD sales figures for the drugs were
given as whole figures and not according to trade name,
since the G03BA03 group was quite small.
SLD Statistics also provided information on the number of
packages sold per year from 1993 to 2004. Based on these
statistics and SLD statistics on the value of testosterone
sold per year, it was possible to calculate the average price
per package sold.
2) The Social Insurance Institution (SII) and the National
Agency for Medicines (NAM) provided statistics on the use
of testosterone medicines in Finland.
Sales and consumption were also studied on the basis of
Finnish Statistics on Medicines, provided by the National
Agency for Medicines (NAM) and the SII since 1993
(National Agency for Medicines and Social Insurance
Institution 1994). Sales statistics for ATC code G03BA03
testosterone were obtained from 1993 to 2004 as well as
the wholesale figures for those drugs.
3) Health 2000 Survey by the National Public Health
Institute. Health 2000 was a population-based health
survey carried out in Finland between autumn 2000 and
spring 2001, consisting of a sample of 10 000 persons aged
18 and over (National Public Health Institute 2005,
National Public Health Institute 2004, National Public
Health Institute 2002).
The quantitative part of the study – in other words, article
IV, the material of which consisted of the drug sales
statistics from Finnish Pharmaceutical Data Ltd., the
Social Insurance Institution Statistics and the Health 2000
Survey by National Public Health Institute – was analysed
by drawing charts of testosterone consumption in relation
to regions, time and ageing male population.
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4 RESULTS
4.1 The normalisation of the treatment for male
menopause
The number of articles published on male menopause grew during
the study period. In the materials researched, male menopause
was first mentioned in 1982. In that first article it was explained
as a mid-career crisis and a related feeling of depression. Male
menopause was defined as a social phenomenon and as being a
consequence of the rupture in working culture created by
automation. The journalist that had written the article saw male
menopause as threatening especially those men with less
education and not many activities outside of work. He expected
the problem to become more prominent when the large baby-
boom generations reached midlife. In 1985 and 1989 journalists
used the term ‘mid-life crisis’ and considered male troubles to be
more mental and psychosocial or more associated with general
ageing than with low male hormone levels in the blood. They
wrapped the term ‘male menopause’ in quotation marks and
described it as being different to the suddenness and finality of
female menopause.
Half of the articles studied were published in the 1990s. At
the beginning of the decade, it was written quite critically that our
culture idealises physical activity and youth, and nourishes hopes
and attitudes that are not in balance with natural changes. Three
years later, male menopause was considered more as a
physiological phenomenon and the expression the production of
testosterone ceases was used. Some journalists wrote that
testosterone medication would restore normal values of
testosterone, but on the other hand expressed the idea that it was
normal that testosterone production begins to decline on average
after 50 years of age.
In 1996, it was written in an article that it was clearly evident
that men experienced menopause, and that the phenomenon had
always existed though only recently had it been talked about. In
the next year some journalists used the term ‘male menopause’
even though they stated that when considering it under tight
criteria, male menopause was a rare phenomenon. Male
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menopause was said to be a life phase that could potentially last
for decades. The clinical category of male menopause or andro-
pause was constructed through the presentation of more specific
diagnostic criteria: where a symptomatic lack of testosterone had
to be verified by a blood test.
From 1999 onwards, journalists still anticipated the incidence
of andropausal problems would increase because of the ageing
Finnish population, and they even used the term ‘andropausal
decades’. In 2000 and 2001, journalists were able to present
criteria on normal testosterone concentrations: they should vary
between 10–35 or 9–38 nmol/l. According to one article, a man’s
testosterone level would go down after 40 years of age by about
one percent a year, but that despite this, researchers talking about
male menopause see decreasing testosterone values as almost
always a sign of an illness.
By the end of the research period, the main viewpoint was
that male menopause called for treatment. Several authors
recommended that men would see their doctors to be ‘on the safe
side’. A man who went to be medically examined was considered
an enlightened pioneer. When the Finnish Medical Association
approved training in the subspecialty of andrology in 2001
(Finnish Medical Association 2001), journalists of the popular
press considered that to be beneficial for ageing men.
During the whole period studied, journalists presented
diverse opinions on both the age at which male menopause occurs
and the prevalence of symptoms associated with it. The most
typical age given for male menopause was 50 years, with the
range being between 35 and 80 years. The stated prevalence of
male menopause varied between 1% and 33%. Throughout the
study period, authors associated male menopause mostly with
insomnia and other sleep disorders, general depression and
melancholy, mood swings, anxiety, lowered stress tolerance, and
tiredness.
In the late 1990s, journalists brought up doctors’ conflicting
attitudes towards testosterone and recommended consideration
before starting the treatment. They wrote that male HT for
andropause was reconstructive and beneficial, and it would
lengthen the male life expectancy. Men were expected to benefit
from the therapy as much as women do from their HT, but
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healthy men should not be treated. A more critical journalist saw
the treatment of midlife crisis with hormones as one aspect of
seeking answers to non-medical problems from medicine.
In 1999 the testosterone patch entered the Finnish market and
the headlines declared that the patch will replace lost
testosterone. Journalists predicted that come the turn of the
millennia, men in menopause would be as easily treated with
hormones as women, and that the use of hormonal treatments
might double if men got sufficient appropriate information about
the symptoms of ageing and knew how to obtain treatment. Some
writers still questioned whether these treatments, which could
potentially span from a man’s midlife until the end of life, would
predominantly benefit the pharmaceutical industry. It is worth
noticing that some of the most frequently quoted experts in the
articles were physicians running several research projects partially
funded by pharmaceutical companies, or who had been employed
as researchers in companies manufacturing and marketing
preparations used in male HT (See Vainionpää & Topo 2006).
The results suggest that there is a tendency towards the
medicalization of men’s midlife and ageing, with testosterone
replacement therapy being an example. The enormous potential
market for male HT means that there are high stakes involved in
deciding whether to promote or to prevent further dissemination
of the therapy and thus the further medicalization of men’s
ageing.
4.2 Finnish Medical Society approves andrology
In medical texts published during the 1980s and 1990s, the
concept of a male menopause or andropause was not specifically
used and, although the term ‘male climacteric symptoms’ was
used, there was no mention of causal factors. This changed during
the 2000s when a paper titled ‘Andropause’ was published in both
a medical journal and a gynaecology textbook. It proposed that
several illnesses and unhealthy habits, such as smoking, excessive
alcohol consumption and a lack of physical exercise, contributed
to the decline of androgen levels.
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The texts were characterised by vagueness in the definition of
andropause (male menopause), but the most frequent gloss was a
state of hypogonadism that emerges with ageing (viz. older ages),
and presents symptoms such as lowered libido. There were,
however, many references to the uncertainty about whether
‘andropause’ is a medical condition requiring treatment or a
symptom of normal ageing.
The proportion of men expected to experience andropause
varied in the texts from 20 to 45 per cent: The proportion that
suffered symptoms increased with age from about the age of 50.
For men aged over 80, 30 per cent were said to have serum
testosterone concentrations under the normal values. The highest
cited prevalence of ‘testosterone deficiency’ was 45 per cent of
men aged 61–70 years.
The authors of the 2002 edition of a urology study book
stressed that biochemical analyses alone were insufficient to
inform practice and that the physician’s clinical findings should
be instrumental. On the basis of biochemical changes,
hypogonadism was said to be found in only seven per cent of men
aged less than 60, but was found in 20 per cent of older men. The
evidence from medical practitioners was, however, that the
symptoms of andropause were far more prevalent. Andropause
was thus a condition to be recognised by the physician rather than
biochemistry.
The list of the symptoms of andropause has expanded
through the 1990s and to the present day. By 2001 it included
physical, mental and cognitive disorders such as the decline of
vitality, tiredness, irritability, depression and libido, erectile
disorders, sweating, the loss of muscular mass and strength, and
the increase in fat tissue in the centre of one’s corpus. A
weakening of memory has also been associated with lowered
concentrations of androgens. The symptoms are mild in the
beginning and they cannot necessarily be associated with
hormonal changes. The 2002 edition of the urology study book
provided the longest list of symptoms of andropause, but still tied
the syndrome to ageing.
In 2001 specific guidelines for testosterone therapy were
given. Undertaking androgen treatment should always be based
on both careful mapping of the symptoms, clinical examination
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and on laboratory test results that favour the treatment. The
quantification of the testosterone levels – especially of free
testosterone – was often said to aid decision-making. If a man had
distinct symptoms of andropause and his concentration of
testosterone in serum was less than 10 nmol/l, androgen therapy
was often said to be beneficial. If the concentration was between
10–15 nmol/l, one could consider a three-month trial treatment.
The clinical evidence was said to be the most important indicator
of the response of the therapy.
The difference between men and women was highlighted
when a medical journal wrote that, in contrast to women, men’s
andropausal symptoms appeared slowly, and therefore they were
not always recognised and might not be associated with the
decline of male hormones.
This literature review and analysis showed that in the medical
construction of the male menopause and its treatment, two issues
remained controversial: the interpretation of normal and abnormal
testosterone levels, and the criteria for starting testosterone
treatment. In fact, some authors did not regard low testosterone
levels as being the main criterion for testosterone treatment but
rather the clinical response, i.e. a patient’s own feelings were the
best indicator of the success of the treatment. It is of course
fundamentally illogical to base the decision to treat on a yet to be
known outcome. Making patient’s subjective feelings the
indicator of the success of hormone treatment is, firstly, the
antithesis of the ideology of evidence-based medicine and,
secondly, argues that success is a discursive matter and an issue
of interaction between the doctor and patient. This may indicate
that practising physicians and medical students are directed
towards treatments with medications without the support of
evidence-based knowledge. Recent findings have shown no
correlation between andropausal symptoms and serum
testosterone levels (Perheentupa et al. 2004).
4.3 Persuading Finnish men to use testosterone
In the WWW texts studied, male menopause was presented both
as a disease and as something that a healthy lifestyle could
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prevent. The most frequent theme in the texts was the goal of
pursuing health. Examples of the banner headlines of the web
pages examined were as follows:
• ‘Good ageing’,
• ‘Finding out the diagnosis,
• ‘A treatment suitable just for you!
• ‘Exercise!’
This kind of discourse can be described as healthism, where
health was almost like a religion. To be a decent citizen one had
to pursue health or at least ask for health services. One
pharmaceutical company advertised as follows: ‘Getting old is
natural. Feeling old is optional’ (Organon 2005).
Some examples of the data described a quasi-professional
attitude which presented itself indirectly: The web page headlines,
such as ‘a well-studied and noticeably good treatment’ underlined
the idea of solid scientific knowledge on the issue, and the reader
of the texts was persuaded to believe in the scientific validity of
the WWW texts.
Because scientific knowledge is still very limited in all
questions related to the male menopause, uncertainty was
discussed, for example, when testosterone treatment was
recommended at least experimentally:
… Many symptoms associated with ageing may be due to
declined levels of testosterone… You may not take it
seriously, because you think that they are normal symptoms
of ageing… Even though the symptoms may be associated
with normal ageing, this isn’t always the case…
(http://www.testosteroni.fi/scripts/consumer/02_diagnosis_
treatment/index.php)
However, uncertainty was presented to a minimal degree.
The risks were often hidden or minimized in the texts but
could still be recognized especially when long-term testosterone
treatment was discussed. According to the WWW pages of
Schering, men using long-term testosterone therapy could develop
polycythemia (i.e. abnormally high red blood cell count), and that
was why the users of Testogel® should have their red blood cell
count checked regularly.
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The male clinics’ and the pharmaceutical companies’
websites discussed men’s sexual dysfunctioning due to male
menopause, declined libido and potency. One clinic emphasised
sexuality as part of the quality of life and in this way made the
treatment of sexual disorders worthwhile. The good sex theme
was present on most web pages either directly or indirectly.
The mood-lifting effect of testosterone treatment was
discussed and an argument for testosterone treatment as a
normalising process was presented. The mood-lifting effects
could be seen in the following: Testosterone has a significant
affect on health and well-being, and also affects the mood and the
level of energy…  The decline in the levels of testosterone
causes…  depression…  When your patient uses Testogel®
preparation, you will notice improvement in his mental and
physical well-being in a few weeks. (Schering 2004). Here the
Schering’s writers were giving hints to physicians that their
testosterone preparation might also help in depressive states.
Knowing that depressive disorders are a major public health issue
in Finland, the mood-lifting effect of testosterone therapy might
open quite a large market for the preparations.
The idea of ‘taking care of yourself’ was also constructed in
several headlines on the web pages. The headlines included:
· ‘Do I suffer from a lack of testosterone?’
· ‘How do I find a suitable doctor?’
· ‘Do I have andropause?’
In the U.S., the National Institute on Aging and the National
Cancer Institute requested in 2002 that the Institute of Medicine
conduct a study to independently assess testosterone therapy. As a
result, the Committee on Assessing the Need for Clinical Trials of
Testosterone Replacement therapy in the Institute of Medicine
(hereafter referred to as the ‘Committee’) was formed.
Subsequently, the Committee published a book in the beginning
of 2004 entitled ‘Testosterone and aging: clinical research
directions’.
According to the Committee (p. 17), levels of plasma
testosterone reach a normal male adult level of 10 to 35 nmol/litre
by about the age of 17, and remain at this level until men are in
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their 30s and 40s, when levels begin to decline at about 1.2 per
cent per year. According to Snyder (2004), the serum total
concentration decreases from a mean of 20.8 nmol per litre at age
30 to a mean of about 13.9 nmol per litre at age 80, and the range
is wide at all ages. An as yet unanswered question is whether this
decrease in testosterone concentration is physiologic, possibly
conveying a benefit, or pathologic, causing harm.
On the AstraZeneca web pages (AstraZeneca 2005) it was
claimed that according to clinical studies the Atmos® patch raised
the serum testosterone level to a normal level, which was
approximately 20 nmol/l. The private clinic Mehiläinen stated
that the levels of testosterone begin to decline at the age of 40, but
the decline is clinically significant only after the age of 50. The
Schering website stated that nowadays it was known that blood
testosterone concentration declines slowly but naturally as part of
ageing. Further, the pages continued by stating that treatment with
testosterone gel leads to testosterone concentrations rising to
normal levels. The Organon website stated that although a decline
in testosterone levels will occur in virtually all men as part of
ageing, with adequate dosing, Andriol® and Andriol Testocaps®
could restore plasma testosterone levels to within normal range.
According to the Committee (p. 81, 89, 93), the influence of
testosterone on prostate carcinogenesis and other prostate
outcomes remained poorly defined, but could greatly influence
the risk-benefit ratio for supplementation in both young and
elderly populations. Also, since the trials to date had been short,
with small numbers of participants, it was not expected that
effects on long-term prostate outcomes would be evident.
According to the Schering web pages, it was important to
examine a man’s prostate before starting the treatment, but
according to present knowledge, the testosterone therapy itself did
not cause, for example, prostate cancer. However, testosterone
might accelerate the growth of an already existing tumour. On the
same lines, AstraZeneca stated that androgen therapy may, as a
long-term treatment in elderly men, increased the risk for prostate
hypertrophy and prostate cancer. Here pharmaceutical companies
minimised the risks even though they admitted their existence.
The themes in the commercial web texts mixed advertising
with knowledge in a way that it is hard to distinguish, even for a
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researcher: What is fact and what is commercial information? The
uncertainty theme present in the texts is problematic for the text
providers, but maybe a lay person does not even notice the factor
of the ‘unknown’ in the web texts.
4.4 The growth of testosterone sales
The most important findings of the sub-study IV can be
summarised under in five points: First of all, the total number of
men receiving a refund for testosterone declined from 7931 in
1996 to 6557 in 2004. Secondly, the number of men receiving a
Special Refund Category reimbursement for testosterone rose
from 1090 in 1996 to 1628 in 2004. Thirdly, at the same time, the
sum per man spent on testosterone almost doubled; a change from
€ 106 in 1996 and € 201 in 2004 (National Agency for Medicines
and Social Insurance Institution 1997, National Agency for
Medicines and Social Insurance Institution 2005). Fourthly, a
change is occurring in that men’s reimbursements for testosterone
are moving from the Basic Refund group to the Special Refund
group, and fifthly, the growth was most vigorous in the capital
area.
The increase of DDDs per 1000 inhabitants for group G03BA
in Finland shows an evident growth from 0.51 in the early 1990s
to 0.64 in 2004 (see Figure 1) (National Agency for Medicines
and Social Insurance Institution 2005, National Agency for
Medicines and Social Insurance Institution 1994).
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(Source: Suomen LäädeData 2004 and National Agency for Medicines and SII
1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005.)
Figure 1. Drug consumption in the class G03BA03
testosterone, as DDDs and the wholesale of
testosterone in Finland 1993–2004.
Testosterone’s wholesale value in 1993 was put at € 472 900. In
the final year studied, 2004, it was € 913 400 (See Figure 1.).
According to the SII and the National Agency for Medicines
(NAM) of Finland (National Agency for Medicines and Social
Insurance Institution 2005), the retail value of medicines can be
approximated from the wholesale value by multiplying it by 1.6.
Thus, the value of retail prices of testosterone in 2004 was €1 461
440. The number of men receiving reimbursement in the Basic
Refund Category slowly declined from 6891 in 1996 to 5035 in
2004 (National Agency for Medicines and Social Insurance
Institution 2005, 146; Social Insurance Institution 2005).
The growth was most rapid in the Helsinki district, where it
was 85% over the five-year period. The ageing of the male
population in the areas of Tampere University Hospital District
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and Helsinki University Hospital District developed in parallel
with each other, but the use of testosterone grew only 35% in five
years in the Tampere area (see Figure 2). The percentage growth
over this five-year period was 78% in the Helsinki Region, 33%
in the Tampere Region and 60% in the Oulu region (See Figure
2).
(Source: Finnish Pharmaceutical Data and Statistics Finland 2005.)
Figure 2. The number of aged men (? 50v) and the
number of testosterone sales in hospital regions.
The growth was most vigorous in the capital area, as expected
given the theory about the diffusion of medical innovation (Banta
1990). In the period from 1993 to 2004, the final five-year period
saw the most vigorous growth, with the costs of the medications
per package rising most in 2004. The growth in the number of
aged men in Finland did not explain the growth in testosterone
sales, as can be seen in Figure 2. The development of female
hormone use in Finland also followed the same pattern, as did for
example the use of vitamin supplements (Klaukka, Riska &
Kimmel 1985; Rahkonen & Hemminki 1988). The innovation
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diffused from highly educated women to others and from the
metropolitan area to rural areas.
Physicians started to prescribe more expensive testosterone
preparations than previously. Increases in the price of a packet of
testosterone preparations became common especially in 2004.
The testosterone gel and the injected testosterone solution
received marketing authorisation from the National Agency for
Medicines in 2003. Male hormone patches designed especially for
the male menopause have been available in Finland since 1999.
The growth of the Special Refund Category may be due to the
fact that physicians have started to regard the diagnosis of low
testosterone concentrations more seriously and write their patients
a certificate stating they have a severe malfunction of the sexual
glands or that men that have formerly received the special refund
right live longer and thus, remain visible in the statistics for
longer.
When evaluating the increase in testosterone consumption
figures, it should be remembered that there are also other
indications for testosterone than male menopause: weakening of
the libido (which can also be interpreted as a sign of male
menopause), male infertility and general dysphoria. At the
moment, testosterone therapy is in the Special Refund Category
on the basis of the following indications: severe malfunction of
the gonads, anterior pituitary hypofunction, breast cancer and
aplastic anemia. Infertility treatments might be also considered
another reason for the growth besides andropause treatment.
However it is highly unlikely that the other Special Refund
Category indications would alone explain the increase in
testosterone use.
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5 DISCUSSION: MALE MENOPAUSE, BIOPOWER AND
MEDICALIZATION
5.1 Inventing male menopause
Michel Foucault’s concept of ‘biopower’ offers a fruitful way to
elaborate on the construction of the male menopause and the
question of knowledge in relation to it. The first pole of
Foucauldian biopolitics focuses on species body, the level of
health, life expectancy and longevity – this applies through the
whole population and is called the surveillance of populations
(Foucault 1980b, Turner 1992.). The aims of male menopausal
treatments’ have similarities with the Foucault’s biopolitics’ at the
population level: to improve life expectancy and longevity and to
ensure people are ready and fit to work (Foucault 1980b, 139).
Male hormone therapy is one example of how medical treatment
can be used to take care of whole population’s body or of the
bodies of a large group of people.
The second pole of Foucauldian biopower works at the
micro-level and is centred on the body as a machine: its
disciplining, the optimisation of its capabilities, the parallel
increase of its usefulness and its docility, its integration into
systems of efficient and economic controls: all this is called
anatomo-politics of the human body and works on the individual
body (Foucault 1980b, 139). One aim is also to control the
individual (Turner 1992). Foucault also turns a man’s interest into
self-control i.e. self-surveillance. This is referred to as ‘techno-
logies of the self’ (Foucault 1988).
This self-surveillance coincides with the presentation of
Clarke et al. (2003) on biomedicalization, the basic idea of which
is that “the focus is on health itself and the elaboration of risk and
surveillance biomedicines” and that leads to the “transformations
of bodies to include new properties and the production of new
individual and collective technoscientific identities” (Clarke et al.
2003, 161). Foucault and Clarke et al. share similar thoughts. In
terms of biomedicalization, it can be argued that men in their mid-
lives would be obliged to take care of their risks and prevent
possible diseases. They would also be expected to consume
biomedical goods and services to be a decent citizen. Health itself
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and the proper management of diseases are becoming individual
moral responsibilities. During the biomedicalization era, the
‘technologies of the self ‘(Foucault 1988) are made visible and
also form a self-governance that people apply to themselves. Male
hormone therapy could be taken as one of those technologies
based on this biomedicalization thesis.
The textual analyses that are presented in Articles I, II and III
are examples of the constitution of docile subjects. A middle-aged
man concerned about his health may not make the assumption of
suffering from andropause at first glance when reading the
‘informative’ texts, but he may assume that he is reading
scientific information about a newly discovered disease and start
to worry if and when he would suffer from andropause. The list of
symptoms is quite general and every man is likely to experience
them (such as being tired). But here, the symptoms become
indicative of a testosterone deficiency. Foucault’s notion on
docile bodies becomes visible in the way that men are supposed
to monitor their own bodies (vs. technologies of the self). Clarke
et al.’s ideas could be used in the same way in the future.
Male menopause and male hormone therapy can also be seen
as examples of Foucauldian technologies of the self. Nowadays it
is not only women who regulate themselves through their bodies
but also men. Men likewise hide their age by dying their hair and
use the services of plastic surgeons to lift their eyelids. Active
middle-age goes on and on, and it would seem that the
technologies of the self (Foucault 1988) erase ageing. Morris
(1998) paraphrases this development with the words ‘utopian
bodies’. Powell and Biggs (2004) examined the maintenance of
good health, the use of counselling narratives and bodily
enhancement. They concluded that these technologies reflect the
different ways in which the ageing self has been re-shaped by
medical experts in postmodern times (Powell & Biggs 2004). It
could be argued that male hormone therapy is one of these
technologies that facilitate graceful ageing.
The Foucauldian notion that the truth is produced in
discourses (Foucault 1980a, 115–119) which act themselves as a
truth also makes sense in the context of this study: In spite of no
solid scientific evidence about the existence of the male
menopause (Rhoden & Morgentaler 2004; Snyder 2004), the
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influential discourses presenting male menopause as a fact are
found in professional and lay text and on the Internet. They have
established a regular discourse on male menopause within the
scope of certain bodily signs that have become symptoms of male
menopause. The more that people read and hear about men having
menopause, the more they are familiarised to this concept and the
more it may shape their thinking about men’s ageing.
Discourses on male menopause have also affected Finnish
physicians, as they have begun to take low testosterone
concentrations more seriously and to medicate their patients with
testosterone (e.g. Pöllänen & Tammela 2001). As recent figures
show (Vainionpää 2006, in press), testosterone use has grown
rapidly. Of course, the entire increase cannot be understood as
simply due to the male menopause discourse. Doctors may write
more frequent certificates that the patient has severe malfunction
of the sexual glands. Those patients may also live longer than
before so they would affect testosterone consumption statistics for
longer. Maybe the use of testosterone in infertility treatments has
also affected the rapid rise of the testosterone use (Vainionpää
2006, in press).
The critical evaluation of the medical information and
knowledge in relation to male menopause is of utmost
importance. In everyday practice, physicians have to work based
on ‘recipe knowledge’ (Berger & Luckmann 1967; Freund &
McGuire 1991), i.e. the knowledge that helps them in their work
and that is supposed to be valid. Physicians have to work based
on a ‘recipe’ simply because they do not have time to study
whether or not, for example, andropause is a genuine or false
phenomenon. That is the case when go-betweens have their place:
medical marketing executives, pharmaceutical companies and
even the authors of medical text books convert research results
into ‘recipe knowledge’ and new treatments.
5.2 Traditional medicalization
The classic definitions of medicalization (Zola 1972; Conrad &
Schneider 1980b; Conrad 1992) do help in understanding the
construction of the male menopause and the subsequent use of
47
male hormone therapy. The existence of the male menopause as
an illness is gradually accepted as is also its treatment.
The conceptual level of medicalization (Conrad & Schneider
1980b; Conrad 1992) is obvious: we have started to call men’s
ageing by a new name: ‘male menopause’ or ‘andropause’ and
men too have their ‘climacteric symptoms’. The title of the
specialists who treats these men – an ‘andrologist’ – also signifies
a conceptual medicalization.
On the institutional level (Conrad & Schneider 1980b;
Conrad 1992), much has happened during the study period. The
most significant event is the decision made on the subspecialty of
andrology, which was carried through in September 2001, with
the Finnish Medical Association approving a new subspecialty
training programme in andrology (Pöllänen & Tammela 2001).
An andrologist is a physician specialised in treating male-specific
conditions (androgen deficiency, sexual-related conditions etc.).
The need was explained by the Association with a reference to
‘incoherence in this field of practice’: andrological problems may
be treated by urologists, gynaecologists or specialists in
dermatology and venereology. Hormone replacement therapy for
ageing males was considered an area of interest for andrology,
and among other things, the new subspecialty was thought to be
necessary to improve diagnosis and treatment of the problems of
older men (Finnish Medical Association 2001; Pöllänen &
Tammela 2001). Furthermore, the variable prescribing practices
for hormonal treatments for male menopause was thought to be a
consequence of the few available medications and the
impracticality of their administration (Pöllänen &Tammela 2001).
The new subspecialty, brought about by some opinion-leading
physicians, probably affects the promotion of male menopause in
Finland.
The foundation of male clinics is an important sign of
institutional medicalization. In the Helsinki area, there are several
private clinics offering services to ageing men, while in contrast,
supply in the Tampere area is quite restricted. That may explain
the different growth rates of testosterone sales in the Helsinki and
Tampere areas. The growth in the number of male clinics is a
signal that supply is increasing.
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The most interesting level of medicalization is the inter-
actional (Conrad & Schneider 1980b; Conrad 1992). Interactional
medicalization implies that medicalization happens as a part of
the doctor–patient relationship, when the physician defines the
problem as a medical one (Conrad & Schneider 1980b; Conrad
1992). Previously a doctor might have said to patients that
patients were tired and had been overworking and needed rest
(e.g. see Vainionpää & Topo 2006). Or – if the problem was
sexual – the doctor would have asked if there was perhaps
something problematic with the relationship. Now when there are
medications like testosterone with which to boost oneself, the
doctor prescribes this for his patient. The doctor remains in the
medical discourse and does not to touch on social or psychosocial
issues.
The most interesting example in the data studied was the use
of a metaphor of a man’s car: like a man takes care of his car, he
should take care of himself by seeing an andrologist once a year
(Kauneus ja Terveys Madame 1/2002, Health and Beauty
Madame 1/2002). Even though the medical profession does not
have as much prestige and autonomy as it used to have, it still has
one remarkable thing: power to control access to health care, at
least to those who can afford to pay for it. The profile of middle-
aged men with menopausal symptoms often correlates with men
of high education and salaries, so why not to offer them medical
services? The medical profession is an actor using testosterone
treatment to return the male patient back to a ‘normal man’. As
the subspecialty of andrology in Finland was inaugurated, the
basis for institutional social medical control of men’s ageing was
created (cf. Halpern 1990; Conrad 1992).
The Social Insurance Institution is one of the key actors and
decision-makers over the benefits of health and illness. Illnesses
are defined by the Social Insurance Institution in Finland
according to ICD-10 (International Statistical Classification of
Diseases and Related Health Problems) classifications. The ICD-
10 classification does not include andropause or male menopause,
though female menopause is included.
The medical profession and medical technology, including
pharmacology, are the main agents of medical social control. The
increasing consumption of pharmaceuticals is also one very
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visible part of medicalization. Now the SII (KELA) grants a basic
reimbursement for male hormone medicines: The wholesale value
of androgens was 960 000 € in 2004. Medical agents are usually
the least expensive, the most accessible and the easiest to use
form of health care technology provided to a patient (Montagne
1992) (Conrad &Schneider 1980a; Conrad 1992).
Other forms of medical social control are also found in male
menopause in the form of medical collaboration, i.e. doctors
provide information to their patients and also doctors tend to keep
information to themselves. Doctors also stick to the medical
model and foster their ideas on their patients. Medical
surveillance is mainly turned into Foucauldian self-surveillance
(Foucault 1988) in that men are encouraged to monitor their
health themselves (e.g. to monitor their blood pressure) (Conrad
& Schneider 1980a; Conrad 1992).
The opposite pole is not a passive patient but instead, an
active health care consumer (Henderson & Petersen 2002;
Applbaum 2006). Health is increasingly viewed as something to
be marketed and bought, and this is very different from the classic
era of medicalization (e.g. the medicalization of female meno-
pause). This shift I would choose to term commercial medicaliza-
tion.
5.3 Commercial medicalization
Medicine is organised more like a business nowadays. The
example of Finnish doctors diagnosing and treating low
testosterone concentrations more liberally also shows how
physicians may be medicalised and can even be the victims of
medicalization (see e.g. Leibovici & Lièvre 2002, 866). They are
charged with the responsibility of not only having to treat
illnesses but with trying to enhance health.
The equating of a human being in consumerism is with being
young and beautiful and likewise therefore healthy (Featherstone
1991). This way of pursuing health comes to mean being slim, fit
and also maybe having the power to organize and be disciplined.
The society that seeks efficiency supports itself by means of
modern medicine, which points out the reasons and means leading
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to inefficiency and sickness and also the means to avoid such
(Karvonen 1992). According to Callahan (2003), medical research
tempts us to invest too much hope in it as a means to relieve the
human condition or leads us to excessively commercialising it, to
cutting moral corners, or to diverting attention from the social and
economic sources of sickness. Callahan calls these things the
‘hazards’ that medicine has in addition to its benefits (2003).
Callahan (2003) does not aim to halt research but to enhance the
possibility of research moving forward in the most socially sound
way possible.
The marketing of health care services has become a topical
activity, which includes advertising, influencing patients and their
relatives directly, influencing professional experts or officials, in
other words all persons that make decisions in the field of health
care. The media is involved in marketing through advertisements,
expert interviews and articles etc. For the markets to operate,
products and services must be sold. The easiest to sell are
medicines and medical products, followed by consultations with
physicians. The markets also require services to change so that
they appear to be new (Terveydenhuollon priorisointiryhmä
1995). Since new medicines are more expensive than older ones,
the rise in medical expenses is mostly based on the fact that new
medications replace older ones (Klaukka 2004; 2005a).
Light (2000) described the idea of medical markets as a
“theoretical anomaly”, since medical markets do not meet many
of the elements in classical definitions of a competitive
marketplace. Asymmetry of information and “uncertainty in the
definition, recognition, and the diagnosis of disease states”
particularly distinguish medical markets from ‘normal’ consumer
markets. The advertisings, the development of specific medical
markets and the standardisation of medical services into product
lines have contributed to an increased commodification of
medical goods and services (Montagne 1992). Conrad and Leiter
(2004) further defined the development of medical markets as
being a process whereby medical products, services or treatments
are promoted to consumers to improve their health, appearance, or
well-being. Until about the 1990s, sociologists rarely saw
medicine as any kind of marketplace, but it is becoming clear that
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medical markets are increasingly important in the analysis of
health care (Conrad & Leiter 2004).
Increasing consumption of pharmaceuticals can be seen as a
very visible sign of commercial medicalization (e.g. Heath 2005;
Conrad 2005). Considering female menopause to be an illness had
a lot to do with economic motivations by the end of the 1990s:
Premarin®, the major brand of oestrogen, has been the largest-
selling prescriptive drug in the USA and according to a study by
the Pharmaceutical Research and Manufacturers of America, 372
new medicines were being developed to treat female menopause
(Gonyea 1998). Because of the need to increase profit, medical
experts and the pharmaceutical industry tended to emphasise the
illness nature of the female menopause (Fausto-Sterling 1992;
Kleinmann 1988; Hillier 1982). Male menopause seems to be
even more driven towards ‘being a disease’.
Instead of attempting interpersonal, social or structural
changes to alleviate symptoms, medications are prescribed and
used for relief (Montagne 1992). At first glance, they are the
easiest and cheapest solution: It is easier to medicate a single man
than to pursue societal adjustments. In this way, medicalization
may be more due to governmental policies and reimbursement or
health care payment mechanisms than to a diagnostic or
therapeutic rationale (Montagne 1992). Moynihan and Smith
(2002) argued that governments may even welcome some of
society’s problems being redefined as medical, with the
possibility of new solutions. However, this leads to the further
extending of medicalization.
At the same time, pharmaceutical companies actively involve
themselves in sponsoring diseases and promoting them to both
consumers and prescribers. An ordinary physician is not able to
keep up with the extensive information provided on e.g. male
menopause. In this way, knowledge in the form of advertising
may also contribute to physicians’ knowledge as well, while the
source of ‘knowledge’ remains the pharmaceutical industry (e.g.
Moynihan, Heath & Henry 2002).
According to Abbasi and Smith (2003), patients would
benefit from the disentangling of doctors from drug companies.
Doctors and drug companies must work together but doctors do
not need to be educated by drug companies for example, since the
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result is bias in the decisions made about patient care (Moynihan
2003b). In spring 2005, a report was published in the United
Kingdom on the influence of the pharmaceutical industry’s
declaration that the industry’s goal is to ‘bring patients life-
enhancing medicines’. The industry spends £3.3bn annually on
research in the UK, and over half of all postgraduate medical
education in the UK is funded by the pharmaceutical industry
from its annual marketing budget of £1.65bn (Ferner 2005).
The significance of the pharmaceutical industry as a political
actor in Europe is great (Abrahams 2002). In the USA, activism
in health is manifested in high public expectations and demands
for all that medical science makes possible, no matter the costs or
that there be few benefits. American patients are increasingly in
the cross-fire, with pharmaceutical companies and medical
industries directly promoting new treatments to consumers and at
the same time, managed care companies are trying to limit them.
In the USA, prescription and over-the-counter medications are
marketed directly and aggressively to consumers with the
assumption that that kind of advertising leads people to request
the medications from their physicians (Mechanic 2002).
In April 2000, the US Endocrine Society convened its First
Annual Andropause Consensus Conference in Beverly Hills,
which set out to define ‘andropause’ and decide how it should be
treated. The chairperson of the Conference, Dr. Ronald Swerdloff,
assembled a panel whose task was to come up with
recommendations for clinical practice. The panel acknowledged
that the benefits of testosterone replacement in ageing men had
not been established, but it still recommended that all men over
the age of 50 be screened for testosterone deficiency, and the
screening should start with a questionnaire. The Beverly Hills
conference was funded solely by the pharmaceutical company
Unimed’s ‘educational grant’, and Unimed even put forward
suggestions for some of the panel’s members. Of the thirteen
panelists in the final group, at least nine, including Dr. Swerdloff,
had significant financial ties to the drug company, in the form of
research grants, consulting arrangements or speaking fees. The
recommendations that the Panel gave made reference to the
‘educational grant’ by Unimed, but not to the panelists’ co-
operation with Unimed (Groopman 2002; Swerdloff 2006).
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The roles and actors in the process of medicalization have
changed between the time that female hormone therapy came onto
the market and when male hormone therapy came onto the
market: Rhoden and Morgentaler (2004) suggest that recent
interest in testosterone therapy has been fuelled not only by
increased medical awareness of the effects of hypogonadism, but
also by 1) the marketing of new testosterone formulations, 2) the
media attention regarding hormone-replacement therapy in both
men and women, and 3) the desire of the baby-boomer generation
to maintain vigour and health. Information and advertising are
mixed to a degree that may be considered an example of
‘commercial medicalization’.
In ‘commercial medicalization’, global pharmaceutical
companies have a clear interest in medicalising the common
problems of everyday life (Moynihan & Smith 2002; Moynihan,
Heath & Henry 2002; Freemantle & Hill 2002) and in widening
the boundaries of treatable illness in order to expand markets for
those who sell and deliver treatments (Illich 1976; Payer 1992;
Moynihan & Henry 2006). The Internet provides a way of selling
sicknesses and advertising prescription drugs, which happens to
be illegal in Finland. In this way, the Internet is helping to extend
the process of medicalization.
There are some powerful physicians that consider the
medicalization of ageing as a positive issue. For example, Shah
Ebrahim wrote in 2002 that the medicalization of old age should
be encouraged. He further states (Ebrahim 2002) that older people
are likely to demand cures for wrinkles, baldness, yellow teeth,
menopause and andropause. According to Ebrahim, greater access
to medical care for older people would result in reductions in
mortality and disability, but treatments to combat the ageing
process itself should still be subject to the same regulatory
framework as any new medical technology. Ebrahim emphasises
that in wealthy countries there is no excuse for ignoring the
medical problems of older people or trying to understand them as
social problems and thus leaving them outside the realm of
medicine (2002).
In Finland, according to Vuorenkoski (2004), the rise in
pharmaceutical costs is both an opportunity and a threat to health
care. He names one current trend of medicalization to be
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‘pharmaceuticalisation’ [lääkkeellistyminen]. It means that more
and more solutions for everyday problems are sought in the form
of pharmaceuticals. Thus, medicines are a triumph of industrial
development. With medications, we are able to – besides treating
illnesses – enhance health, reduce risks associated with life,
improve the quality of life and to also seek a longer life. In most
cases these factors can also be affected in non-medical ways, e.g.
changing our lifestyle or our environment (Vuorenkoski 2004).
The National Advisory Board on Health Care Ethics
(ETENE) in Finland concluded in July 2005 that the medicaliza-
tion of everyday life occurs particularly when health care services
become commercial. More minor conditions are treated with what
medicine has to offer, and the health care sector becomes
responsible for matters that it formerly did not have to deal with.
ETENE asked people to pay serious attention to the following
items: that well-being should be promoted by sufficient rest, a
reasonable amount of healthy food, physical exercise, good
human relations and meaningful work and activities (ETENE
2005).
ETENE asked us to demolish the alarming increase in
medicalization, while reminding us of the fact that taking
responsibility for our own lives improves the quality of life of the
chronically ill. Our society should have enough resources to solve
those problems we face and to treat people that need particular
know-how and societal resources (National Advisory Board on
Health Care Ethics (ETENE) 2005).
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6 CONCLUDING REMARKS
The paradox of health is that it is both very personal and
comprehensively public. We desire more and more what we
cannot have in unlimited measure, that is, a healthier, extended
life, and we cannot afford to pursue it much longer without harm
to our personal lives, and other institutions. The nature and
meaning of our ‘health’ is in crisis, as is the place that the pursuit
of health should have in our lives (Callahan 1994).
The costs of new drugs targeted at essentially healthy people
are threatening the viability of publicly funded universal health
insurance systems. These drugs, such as sildenaphil, are also
referred to as lifestyle drugs (e.g. Lexchin 2006). Testosterone
should also be considered a lifestyle drug. Lifestyle drugs may be
a hazard or an opportunity for health policy. The fact that there
are a number of different kinds of lifestyle drugs may force the
decision-makers to consider the notion of medical necessity and
integrating into policy as well as redesigning services (Gilbert,
Walley & New 2000).
At the level of the whole society we must think about what
good health brings to society and what type of health is necessary
for ‘a good society’. The pursuit of good health is understandable,
since some degree of good health is a necessary condition for
living with ourselves and living with others. However, we cannot
afford to seek endless satisfaction in terms of individual health
care needs, since the possibilities of medical progress are endless
(Callahan 1994).
That leads us to ask the critical question: at what price –
economically, politically and ethically – will the vision of good
health be realised. There will arise a widening gap between what
is medically possible and what is medically customary, and that
will create conflicts between patients, health care providers, and
health policy actors. The nation as a whole will be confronted
with a difficult choice: to continue fostering the use of
technologically advanced techniques and accept a steady rise in
health care expenditures, or to limit the availability of these
techniques in order to keep the costs rational (Schwartz 1998).
Therefore I claim that we have to choose between promoting
medicalization or prioritising health care.
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Whose is the problem of extensive medicalization? In
Finland, it is most of all the problem of the Finnish government,
since the government carries a large part of the responsibility for
medical costs in one way or another. Medicalization tends to raise
costs and thus, leads to the need for prioritisation. But
medicalization may also cause difficulties for individuals that
encounter medical problems: One may encounter health problems
and would like to deal with them in quite natural ways, even
though advice is sought from a physician. A physician may
though disagree and treat a minor health concern in a heavy
manner. Alternatively, as the need for prioritisation increases due
to medicalization, a man needing medical treatment does not
receive it from the public sector because of scarce resources.
According to Klaukka (2004), when choosing a medication, a
physician should take into account the differences in efficacy and
safety of different options; to be mindful that with the newest
medications, it needs to be asked whether their safety is evidence-
based and whether their benefit is clinically proven to be
significant, and take care to motivate the patient in making
lifestyle changes that are important in terms of his illness. Not
necessarily the newest medications are the best and not
necessarily does every single health trouble need medical
treatment. For example, fever is nature’s own way of killing
bacteria and allowing resistance to develop against the next attack
of the virus. If one reduces the fever immediately with painkillers,
the resistance has no time to develop and when the person meets
the flu virus again, he will probably get the flu again.
In general, problems with sexual performance seem to have
become more overt in the most recent publications and by the
2000s were mentioned as the most important symptoms of low
androgen concentrations in men. This coincided with the entry of
Viagra® into the Finnish market and its successful marketing
campaign. Testosterone patches reached Finland in 1999 and were
described in a substantial article on erectile disorders. Men as
private health care consumers are a new market area and Viagra®
may have referred them to this new role. Testosterone has a ready
market or at least men are accustomed to medications that have an
effect on their sexuality. The quality of sex life is again one
example that is impossible to evaluate medically because the
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expectations that are set are culturally constructed and can
basically be unlimited.
The evidence from the reviewed documents for this study is
that Viagra® may have promoted the dissemination of
testosterone treatments. On the other hand, sildenaphil has
replaced testosterone as one form of treatment for sexual
functioning, but Viagra® has also raised awareness about male
sexual disorders and that they can be medically treated. The
debate in the Finnish documents on sexuality leads one to ask
whether the drug – with its success in treating sexual disorders –
is directing medical markets towards consumerist demands rather
than clinical needs. Pharmaceutical manufactures are keen to
market medicines that make a patient happy and satisfied, and
thus are easier for physicians to prescribe (e.g. Abbasi & Smith
2003).
According to Carpiano (2001), Viagra® has created a new
model of ‘passive’ medicalization in which the general public has
turned to the medical field for a way to combat the effects of
ageing and socially rooted problems. Waitzkin (1989) suggested
that, for many conditions, doctors tend to prescribe medication for
a patient’s problem but overlook aspects of the patient’s lifestyle
that may be creating the problem in the first place, e.g. work
stress or marital problems.
In Finland, it has been asked if there is an alliance between
the pharmaceutical industry, physicians and patient organizations
versus ‘society’, since pharmaceutical allies are significant to
physicians. Studies have shown that even though there are several
short-comings in the prescription of drugs, the pharmaceutical
industry is a central actor in prescribing practices (Hemminki
2004a).
The health policy in Finland in the 1990s and onwards was to
decentralize, and following that, many formerly publicly funded
and governed health services were to be decided upon separately
in each municipality. The major administrative reform affecting
health care in the early 1990s was aimed at increasing account-
ability, by giving more freedom and responsibility to the
municipalities so that they could produce health services with
minimum guidance and control from central government. By
replacing the cost-based central government grant system in 1993
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with sector-specific block grants, based on ‘objective’ criteria of
need and demographic and financial information, municipalities
were given an opportunity to reallocate state subsidies according
to local needs and local political consideration. The financial
support to municipalities was not as high as it was before
decentralization. That led to a state of prioritisation and
municipalities dropped many health services and left only the
basic ones. Those that were axed had to be sought from the
private health care sector, which has co-existed for a long time in
Finland and is partly reimbursed by the Social Insurance
Institution, or if a person is working, they can rely on their
occupational health care (Martikainen & Uusikylä 1997).
In 2004 and partially in 2005, amendments were made to the
Primary Health Care Act in Finland to replace the outdated
former law of 1972. One of the reforms was that in the new
Primary Health Care Act the term ‘health care’ was dropped and
was replaced by the more modern term ‘health promotion’, which
also covers the prevention of diseases and the accidents (Puska
2006).
The development of a new illness named ‘andropause’ or
‘male menopause’ and new services, ‘male clinics’, fits this
postmodern decentralization trend and also to this new ‘health
promotion’ trend. Private health care services are eagerly created
and marketed (e.g. Hemminki 2004a) and the public sector is at
the same time withdrawing into the background and taking care
only of primary elements. People are no longer treated solely in
large units but instead, new smaller and intimate private clinics
exist that offer quality of life and even lifestyle ? but only for those
who can afford it.
Based on this study, it can be argued that Finnish health care
is now in an e-scaped state. Finnish health care legally is run by
the public actors, but the singular prioritizing decisions in the
publicly-funded health care can be made by junior doctors or
doctors with four years medical training, whether they decide to
treat, for example, a patient with osteoarthritis or not. If a Finnish
citizen is not happy with his treatment, he can go to another
doctor. Then the state pays most of the expenses that will come
from treatments and medications.
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On the other hand, during the e-scaped state of health care, in
my opinion, the idea of a traditional doctor–patient relationship,
where the aim is to heal the patient, is under demolition. Instead,
the doctor is the provider of health care services and the patient is
the client in the private sector. In the private sector the doctor is
also an enterpriser. In the public sector, the doctor is the
gatekeeper and his duty is more the responsible use of the scarce
resources of public health care (e.g. Kokko 1998).
Thirdly, there is a private sector providing health services in
Finland, but the Social Insurance Institution (SII, KELA) of
Finland reimburses the doctors’ fees to a large extent, and all
taxpayers foot the costs of the SII. There are no limitations on
how many private health care services are reimbursed per person
in a year. As a result, a situation is possible where all taxpayers
are paying for treatments not simply for curing illnesses, but also
for enhancing health. Fourthly, many people have their own
health insurance in Finland, and this insurance is vigorously
marketed (Koskiaho-Cronström 2003). According to Mattila, the
percentage of personal health insurances in Finland of the adult
group is 3.3 per cent and the percentage for the whole population
10.4 per cent (Mattila 2006).
In 2005, the OECD criticized Finland for inequitable access
to some health services with reference to international
comparisons that suggest access to general practitioners in
Finland is comparatively speaking not equal across income
groups. The employed population has better access to health care
services due to occupational health care, whereas the non-
employed population have to rely on services provided by health
centres and the private sector. The employed population has
access to free occupational health care whereas the non-employed
population, who typically are worse off, must pay for
appointments with general practitioners (OECD 2005). For
example, a man living with a basic unemployment allowance gets
23.50 € per a day and a visit to health care centre costs 11 €.
In our health care system we should introduce only the really
innovative and therapeutically developed medications and leave
for example the ‘innovatively limited’ medications outside our
health care system. Medical expenses could also be cut by
reducing marketing costs (Vuorenkoski 2004). According to
60
Riggs (2004), we should evaluate if we can afford medical
development when it is so expensive.
There is no evidence-based information on male menopause
thus far (Snyder 2004; Rhoden & Morgentaler 2004). If ETENE
recommendations are followed, male hormone therapy for male
menopause should be de-prioritised (ETENE 2005). Also
according to the Committee of The Finnish Medical Society
Duodecim, the most equitable and the most costs-saving basis for
prioritisation is the requirement of the efficiency of the treatments
(Finnish Medical Society Duodecim 2000, 31).
It is ironic that testosterone replacement therapy is being
promoted, for example, in the popular press, despite the
acknowledged lack of evidence (Hoffmann 2001). When the US
government decided in 2002 not to go on with a male hormone
clinical trial, there was hardly any discussion about it in Finland,
but the discontinued research on female HT was widely covered
in the Finnish media (Hemminki 2004b).
Over twenty years ago, Arie (1981) commented that “it is
much more society’s convenience that ‘medicalises’ complex
problems than the avidity of doctors to take responsibility for
them.” More than 40 years ago, C. Wright Mills explored the
connections between private problems and public issues and
pointed out that the troubles a person experiences arose in the
context of broader social problems (Mills 1959). I understand that
‘male menopause’ is an individualised, biologically reduced, and
medicalised version of the social problem called ‘the ageing
society’. Solutions are subsequently sought from medical experts.
Rather than attempt interpersonal, social or structural changes to
alleviate symptom states, diseases and their causes, it seems
preferential to prescribe medication for symptomatic relief.
The validity of the research and the need for future
research
This study had four different data sources: information targeted to
lay people via journals and on the Internet, information aimed at
physicians during their studies and also later, and also quantitative
material on testosterone use in Finland. Advertisements in
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medical journals were excluded even though the pharmaceutical
industry’s ‘semi-informative’, that is advertising texts on the
Internet, were included. Thus, the information content of the
study can be regarded as fairly diverse.
The lay journal material and the physicians’ study and journal
material cover the two decades between 1982 and 2002. The
quantitative study is interested mostly in the recent period of
1999–2004. From the beginning of the 1980s, male hormone
therapy and male menopause was spoken of more frequently. The
period from 1999 to 2004 saw a rapid growth in male HT use.
The era of the birth of ‘male menopause’ in Finland is thus
covered by this study. It should, however, be pointed out that
even if the use of testosterone therapy has increased, it is still
quite rare. Can this be seen as an indication of resistance to
medicalization by ageing men or do we still appreciate the idea of
natural ageing in Finland?
If and when testosterone treatment becomes more common,
an interview-based study on the use of testosterone when ageing
would be much more meaningful with more information from
different sources. A limitation of this current study is that the
experiences of individual users are left out. Also the experiences
of the physicians that treat their patients with testosterone are
missing. The interview study could usefully be carried out in a
few years so as to understand the phenomenon more thoroughly.
What are the motives of the patients wanting testosterone
therapy? Why does a physician recommend HT to his patient?
How often do middle-aged men order HT via the Internet without
medical consultation?
Medicalization is a social and a political process that happens
in time and space with different patterns and actors. It is thus very
challenging to study medicalization empirically since there are
many actor groups. Also a man as a client himself is an actor in
his own medicalization process (Foucault 1988; Clarke et al.
2003), which is the case in male hormone therapy and male
menopause.
The results of this study should raise questions about
unnecessary health needs or health needs that are driven purely by
the pharmaceutical industry. Health policy makers should be
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aware that new illnesses are manufactured and thus reconsider the
allocation of public tax funds to treat such a semi-illness.
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